The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide

Huang-Shen Lin,1,2 Chun-Wen Cheng,3 Ming-Shyan Lin,4 Yen-Li Chou,5 Pey-Jium Chang,2 Jing-Chi Lin,6 Jung-Jr Ye3 1Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lin HS, Cheng CW, Lin MS, Chou YL, Chang PJ, Lin JC, Ye JJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Tuberculosis Oldest old Adverse effect Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/443d666efdfd412cb8a878c5fa45e7af
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:443d666efdfd412cb8a878c5fa45e7af
record_format	dspace
spelling	oai:doaj.org-article:443d666efdfd412cb8a878c5fa45e7af2021-12-02T01:06:40ZThe clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide1178-1998https://doaj.org/article/443d666efdfd412cb8a878c5fa45e7af2016-03-01T00:00:00Zhttps://www.dovepress.com/the-clinical-outcomes-of-oldest-old-patients-with-tuberculosis-treated-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Huang-Shen Lin,1,2 Chun-Wen Cheng,3 Ming-Shyan Lin,4 Yen-Li Chou,5 Pey-Jium Chang,2 Jing-Chi Lin,6 Jung-Jr Ye3 1Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, 3Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 4Division of Cardiology, Chang Gung Memorial Hospital, Yunlin, 5Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 6Division of Allergy and Immunology and Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan Objectives: To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens. Design: A retrospective chart review study. Setting: A 1,200-bed tertiary teaching hospital in southwest Taiwan. Participants: We conducted a retrospective observational study between January 1, 2005 and December 31, 2011. Seven hundred adult patients (aged ≥18 years) with TB treated with RIP-containing anti-TB regimens were reviewed, including 161 oldest old patients. Outcome measures: Clinical outcomes included clinical responsiveness and microbiological eradication. Adverse outcomes included drug-induced hepatitis, and other symptoms included gastrointestinal upset (eg, abdominal pain, vomiting, diarrhea, or dyspepsia), skin rash, joint pain, and hyperuricemia. Results: Compared with the non-oldest old adult patients, the oldest old patients more frequently had hepatitis (P=0.014), gastrointestinal upset (P=0.029), and unfavorable outcomes (P<0.001). In a multivariate analysis, hepatitis during treatment (adjusted odds ratio: 3.482, 95% confidence interval: 1.537–7.885; P<0.003) and oldest old age (adjusted odds ratio: 5.161, 95% confidence interval: 2.294–11.613; P<0.010) were independent risk factors for unfavorable outcomes. In the oldest old patients with hepatitis, rifampicin use was more common in the favorable outcome group than in the unfavorable outcome group (100% vs 37.5%; P=0.001). Conclusion: The oldest old age and hepatitis during RIP treatment were associated with unfavorable outcomes. For the oldest old patients with TB having hepatitis during treatment, rifampicin rechallenge and use might benefit the treatment outcome. Keywords: hepatitis, refampicin, adverse effectLin HSCheng CWLin MSChou YLChang PJLin JCYe JJDove Medical PressarticleTuberculosisOldest oldAdverse effectGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 11, Pp 299-306 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Tuberculosis Oldest old Adverse effect Geriatrics RC952-954.6
spellingShingle	Tuberculosis Oldest old Adverse effect Geriatrics RC952-954.6 Lin HS Cheng CW Lin MS Chou YL Chang PJ Lin JC Ye JJ The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
description	Huang-Shen Lin,1,2 Chun-Wen Cheng,3 Ming-Shyan Lin,4 Yen-Li Chou,5 Pey-Jium Chang,2 Jing-Chi Lin,6 Jung-Jr Ye3 1Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, 3Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, 4Division of Cardiology, Chang Gung Memorial Hospital, Yunlin, 5Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, 6Division of Allergy and Immunology and Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan Objectives: To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens. Design: A retrospective chart review study. Setting: A 1,200-bed tertiary teaching hospital in southwest Taiwan. Participants: We conducted a retrospective observational study between January 1, 2005 and December 31, 2011. Seven hundred adult patients (aged ≥18 years) with TB treated with RIP-containing anti-TB regimens were reviewed, including 161 oldest old patients. Outcome measures: Clinical outcomes included clinical responsiveness and microbiological eradication. Adverse outcomes included drug-induced hepatitis, and other symptoms included gastrointestinal upset (eg, abdominal pain, vomiting, diarrhea, or dyspepsia), skin rash, joint pain, and hyperuricemia. Results: Compared with the non-oldest old adult patients, the oldest old patients more frequently had hepatitis (P=0.014), gastrointestinal upset (P=0.029), and unfavorable outcomes (P<0.001). In a multivariate analysis, hepatitis during treatment (adjusted odds ratio: 3.482, 95% confidence interval: 1.537–7.885; P<0.003) and oldest old age (adjusted odds ratio: 5.161, 95% confidence interval: 2.294–11.613; P<0.010) were independent risk factors for unfavorable outcomes. In the oldest old patients with hepatitis, rifampicin use was more common in the favorable outcome group than in the unfavorable outcome group (100% vs 37.5%; P=0.001). Conclusion: The oldest old age and hepatitis during RIP treatment were associated with unfavorable outcomes. For the oldest old patients with TB having hepatitis during treatment, rifampicin rechallenge and use might benefit the treatment outcome. Keywords: hepatitis, refampicin, adverse effect
format	article
author	Lin HS Cheng CW Lin MS Chou YL Chang PJ Lin JC Ye JJ
author_facet	Lin HS Cheng CW Lin MS Chou YL Chang PJ Lin JC Ye JJ
author_sort	Lin HS
title	The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
title_short	The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
title_full	The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
title_fullStr	The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
title_full_unstemmed	The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
title_sort	clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/443d666efdfd412cb8a878c5fa45e7af
work_keys_str_mv	AT linhs theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chengcw theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linms theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chouyl theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT changpj theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linjc theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT yejj theclinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linhs clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chengcw clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linms clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT chouyl clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT changpj clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT linjc clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide AT yejj clinicaloutcomesofoldestoldpatientswithtuberculosistreatedbyregimenscontainingrifampicinisoniazidandpyrazinamide
_version_	1718403310967324672

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide

Ejemplares similares